We measured 92 proteins involved in inflammation and immune function using a proximity extension technique (Immune-Oncology panel, Olink, Uppsala, Sweden), as previously described18 (link). Of 1473 samples provided (across maximal 500 subjects), we first excluded 7 samples based on technical failure of proteomics. Next, we excluded 18 proteins with expression below the limit of detection or not reported in at least 25% of remaining samples. Finally, we excluded data from 10 individuals who had outlier protein values at any of the time points via principal components analysis (PCA). In this approach, the first principal component of the screening visit protein expression was applied to each timepoint (screening, baseline, 12-month, 30-month) and individuals with an absolute value PC score greater than 5 were excluded. Our analytic sample consisted of 74 proteins across a maximal 490 participants in the analysis (noted as “maximal” as not all participants had samples at every time point; Table S1). Proteomics in FHS were performed using a next-generation sequencing-based Olink platform (Explore 1536, Olink, Uppsala, Sweden)19 (link). Across the 740 FHS participant samples, on average 85% passed quality control validation, leading to a variable number of samples for any given protein.